rx-0201
Nucleic acidexperimental
Clinical trial activity
4 trials · 2 clinical orgs · 0 marketing orgs
Phase 1
2
Phase 2
3
Phase 3
0
Phase 4
0
Earliest trial started May 1, 2009 (NCT01028495)
Timeline
Indications
Mechanism of action
AKT1 inhibitor
Chemistry & pharmacology
- Multi-specific
- No
Oral
No
Parenteral
No
Topical
No
Also known as
- rx-0201
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT06309485 | Phase 2 | Aug 31, 2024 | Government of China |
| NCT05267899 | Phase 1 | Aug 1, 2022 | Government of China |
| NCT02089334 | Phase 1/Phase 2 (Phase 2) | Aug 1, 2014 | Rexahn Pharmaceuticals, Inc. |
| NCT01028495 | Phase 2 | May 1, 2009 | Rexahn Pharmaceuticals, Inc. |
Showing 4 of 4 trials
Page 1 / 1
Organizations
Research & Development (2)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Government of China | Government | 2 | 2 | 2 | 2022 |
| Rexahn Pharmaceuticals, Inc. | For profit | 2 | 2 | 1 | 2009 |
2 organizations
Page 1 / 1